Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Welcome to the Tessa News Link Beta! We are actively improving this experience.

Share Feedback

Source study found

Story checked

DNA 'switch' uncovers new brake on breast cancer growth (opens in a new tab)

medicalxpress.com · 2026-11-06

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 3 other points were not covered by the paper.

  • 4 supported
  • 1 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Four of eight check out. Three claims the study doesn't address.

  • 4 supported
  • 1 overstated
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8OverstatedAdelaide University researchers found a DNA "switch" that helps the body stop the growth of the most common form of breast cancer.View evidenceHide evidence

Why this verdict

The abstract-level profile supports discovery of an AR-responsive intronic enhancer, HRR INT3, that contributes to AR-mediated growth suppression in cancer cell-line models. But the headline wording—“helps the body stop” breast-cancer growth—outruns the evidence by implying an in-body/clinical tumor-control effect rather than in vitro mechanistic evidence. The headline also outruns the story body’s caveat that the work is model-based and future-oriented.

1

Study evidence

AR occupancy was mapped to a conserved intron 3 hormone response region (HRR INT3) within the ZBTB16 locus in breast cancer models and clinical specimens.

“AR bound a conserved intron 3 hormone response region (HRR INT3 ) within the ZBTB16 locus in breast cancer models and clinical specimens, with androgen-dependent H3K27ac enrichment, consistent with an AR-responsive enhancer.”
2

Study evidence

CRISPR/Cas9 deletion of HRR INT3 prevented AR-dependent induction of ZBTB16.

“HRR INT3 CRISPR/Cas9 deletion prevented AR-dependent ZBTB16 induction, impaired AR-mediated growth suppression, attenuated canonical AR target-gene activation and increased baseline proliferation across breast and prostate cancer cells with upregulation of E2F targets.”
Claim 2 of 8Not coveredThe study says up to 80% of breast cancer cases are estrogen receptor-positive (ER+), meaning their growth is driven by estrogen.View evidenceHide evidence

As statedup to 80%

Why this verdict

The supplied abstract-level paper profile concerns ER+ breast cancer biology but does not provide or verify the epidemiologic statement that up to 80% of breast cancers are ER+ or the simplified definition that their growth is driven by estrogen.

Claim 3 of 8Not coveredPrevious research had shown that the androgen receptor can act as a tumor suppressor in ER+ breast cancer, and activating it has shown promise as a treatment strategy.View evidenceHide evidence

Why this verdict

The profile supports the background premise that AR acts as a tumour suppressor in ER+ breast cancer. However, at abstract depth it does not verify the fuller story framing that AR activation has already shown promise as a treatment strategy.

1

Study evidence

Androgen treatment increased ZBTB16 protein in ER+ breast cancer cell lines.

“Androgen treatment increased ZBTB16 protein in ER + breast cancer cell lines, but ZBTB16 knockdown or overexpression did not detectably alter AR anti-proliferative effects in the models tested.”
2

Study evidence

CRISPR/Cas9 deletion of HRR INT3 prevented AR-dependent induction of ZBTB16.

“HRR INT3 CRISPR/Cas9 deletion prevented AR-dependent ZBTB16 induction, impaired AR-mediated growth suppression, attenuated canonical AR target-gene activation and increased baseline proliferation across breast and prostate cancer cells with upregulation of E2F targets.”
Claim 4 of 8Not coveredThe article says the finding could help develop better ways to identify and treat patients with advanced ER+ breast cancer who have stopped responding to hormone therapies.View evidenceHide evidence

Why this verdict

The supplied profile supports mechanistic in vitro findings and a secondary clinical-cohort association for ZBTB16 expression and survival, but it does not verify the more specific translational claim about developing better ways to identify and treat advanced ER+ breast cancer patients who have stopped responding to hormone therapies. That may be a discussion-level implication, but it is not established at abstract depth.

1

Study evidence

ZBTB16 mRNA expression was reduced in breast tumours relative to normal breast tissue in clinical cohorts.

“In clinical cohorts, ZBTB16 mRNA expression was reduced in breast tumours relative to normal tissue, and higher expression correlated with improved survival in ER + disease.”
2

Study evidence

CRISPR/Cas9 deletion of HRR INT3 prevented AR-dependent induction of ZBTB16.

“HRR INT3 CRISPR/Cas9 deletion prevented AR-dependent ZBTB16 induction, impaired AR-mediated growth suppression, attenuated canonical AR target-gene activation and increased baseline proliferation across breast and prostate cancer cells with upregulation of E2F targets.”
Claim 5 of 8SupportedThe researchers say changing ZBTB16 levels in breast cancer cells did not alter the androgen receptor's ability to suppress cell growth.View evidenceHide evidence

Why this verdict

The profile states that ZBTB16 knockdown or overexpression did not detectably alter AR anti-proliferative effects in the ER+ breast cancer cell models tested, matching the claim that changing ZBTB16 levels did not alter AR-mediated growth suppression in those models.

1

Study evidence

Androgen treatment increased ZBTB16 protein in ER+ breast cancer cell lines.

“Androgen treatment increased ZBTB16 protein in ER + breast cancer cell lines, but ZBTB16 knockdown or overexpression did not detectably alter AR anti-proliferative effects in the models tested.”
Claim 6 of 8SupportedInstead, they identified an intronic regulatory DNA region inside ZBTB16, called HRRINT3, that acts as an enhancer and is critical for androgen receptor-mediated tumor suppression.View evidenceHide evidence

Why this verdict

The profile supports identification of HRR INT3 as a conserved intronic AR-bound region with androgen-dependent H3K27ac enrichment, consistent with enhancer activity, and CRISPR deletion evidence showing functional involvement in AR-dependent ZBTB16 induction and growth suppression. The support is for cell/model-based tumour-suppressive activity, not clinical efficacy.

1

Study evidence

AR occupancy was mapped to a conserved intron 3 hormone response region (HRR INT3) within the ZBTB16 locus in breast cancer models and clinical specimens.

“AR bound a conserved intron 3 hormone response region (HRR INT3 ) within the ZBTB16 locus in breast cancer models and clinical specimens, with androgen-dependent H3K27ac enrichment, consistent with an AR-responsive enhancer.”
2

Study evidence

CRISPR/Cas9 deletion of HRR INT3 prevented AR-dependent induction of ZBTB16.

“HRR INT3 CRISPR/Cas9 deletion prevented AR-dependent ZBTB16 induction, impaired AR-mediated growth suppression, attenuated canonical AR target-gene activation and increased baseline proliferation across breast and prostate cancer cells with upregulation of E2F targets.”
Claim 7 of 8SupportedUsing CRISPR to delete part of HRRINT3 weakened the androgen receptor's ability to suppress breast cancer cell growth and increased genes linked to cell division.View evidenceHide evidence

Why this verdict

The abstract-level profile reports that CRISPR/Cas9 deletion of HRR INT3 impaired AR-mediated growth suppression and increased baseline proliferation with upregulation of E2F targets, which are linked to cell-cycle/cell-division programs.

1

Study evidence

CRISPR/Cas9 deletion of HRR INT3 prevented AR-dependent induction of ZBTB16.

“HRR INT3 CRISPR/Cas9 deletion prevented AR-dependent ZBTB16 induction, impaired AR-mediated growth suppression, attenuated canonical AR target-gene activation and increased baseline proliferation across breast and prostate cancer cells with upregulation of E2F targets.”
Claim 8 of 8SupportedRemoving the enhancer also increased cell growth in other androgen receptor-positive breast and prostate cancer cell models, suggesting a broader role in restraining tumor growth.View evidenceHide evidence

Why this verdict

The profile reports increased baseline proliferation and related transcriptional changes across breast and prostate cancer cells after HRR INT3 deletion. The story’s broader-role language is appropriately hedged as “suggesting,” and is consistent with the abstract’s cross-model framing.

1

Study evidence

CRISPR/Cas9 deletion of HRR INT3 prevented AR-dependent induction of ZBTB16.

“HRR INT3 CRISPR/Cas9 deletion prevented AR-dependent ZBTB16 induction, impaired AR-mediated growth suppression, attenuated canonical AR target-gene activation and increased baseline proliferation across breast and prostate cancer cells with upregulation of E2F targets.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Clinical cohort analyses found lower ZBTB16 mRNA in breast tumours than normal breast tissue and higher ZBTB16 expression associated with improved survival in ER+ disease.

    This secondary clinical-cohort component is material to the paper’s clinical relevance, but the presented story claims do not report the tumour-vs-normal expression finding or the survival association.

    From secondary_data analysis (clinical cohort gene-expression and survival analysis)

  • The abstract does not provide quantitative effect sizes, statistical details, specific cell lines, replicate numbers, or assay protocols for the mechanistic findings.

    The story does not mention the lack of quantitative or methodological detail available at abstract depth. This limits how strongly the magnitude and reproducibility of the reported cell-model effects can be assessed from the supplied profile.

    From in vitro cell-line perturbation; Chromatin profiling at locus (AR and H3K27ac ChIP in models and clinical specimens); CR

  • The clinical cohort survival association is observational and, at abstract depth, lacks effect estimates, adjustment details, cohort identities, and sample sizes.

    The story does not discuss this observational clinical-cohort element or its limitations. This matters for any implication that the mechanism can already identify or guide treatment for patient subgroups.

    From secondary_data analysis (clinical cohort gene-expression and survival analysis)

4 things the story did carry across
  • HRR INT3 is an intronic AR-responsive enhancer within the ZBTB16 locus, supported by AR binding and androgen-dependent H3K27ac enrichment in models and clinical specimens.
  • CRISPR/Cas9 deletion of HRR INT3 prevented AR-dependent ZBTB16 induction, impaired AR-mediated growth suppression, attenuated canonical AR target-gene activation, and increased baseline proliferation with E2F target upregulation across breast and prostate cancer cells.
  • ZBTB16 protein is androgen-inducible in ER+ breast cancer cell lines, but ZBTB16 knockdown or overexpression did not detectably alter AR anti-proliferative effects in the tested models.
  • Functional evidence for HRR INT3 is in vitro; clinical or in vivo treatment relevance is not established in the abstract-level profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroTest the functional requirement of HRR INT3 for AR-dependent ZBTB16 induction and AR-mediated tumour suppression (growth suppression, canonical AR program) using CRISPR/Cas9 enhancer deletion across breast and prostate cancer cells.CRISPR/Cas9 enhancer deletion (in vitro)Expand

In plain English

CRISPR/Cas9-mediated deletion of a conserved intronic enhancer element (HRR INT3) in cancer cell lines prevented androgen receptor (AR)-dependent induction of ZBTB16, impaired AR-mediated growth suppression, attenuated canonical AR target-gene activation, and increased baseline proliferation with upregulation of E2F targets across breast and prostate cancer models, supporting a functional role for HRR INT3 as an AR-responsive enhancer contributing to tumour-suppressive AR activity.

Key findings

  • CRISPR/Cas9 deletion of HRR INT3 prevented AR-dependent induction of ZBTB16.
  • HRR INT3 deletion impaired AR-mediated growth suppression.
“HRR INT3 CRISPR/Cas9 deletion prevented AR-dependent ZBTB16 induction, impaired AR-mediated growth suppression, attenuated canonical AR target-gene activation and increased baseline proliferation across breast and prostate cancer cells with upregulation of E2F targets.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroValidate ZBTB16 as an androgen receptor (AR)–regulated tumour-suppressor-related target in ER+ breast cancer models and assess whether ZBTB16 mediates AR anti-proliferative effects.in vitro cell-line perturbationExpand

In plain English

In ER+ breast cancer cell lines, androgen treatment increased ZBTB16 protein expression, but genetic perturbation of ZBTB16 (knockdown or overexpression) did not detectably modify AR-mediated anti-proliferative effects in the models reported.

Key findings

  • Androgen treatment increased ZBTB16 protein in ER+ breast cancer cell lines.
  • ZBTB16 knockdown or overexpression did not detectably alter AR anti-proliferative effects in the models tested.
“Androgen treatment increased ZBTB16 protein in ER + breast cancer cell lines, but ZBTB16 knockdown or overexpression did not detectably alter AR anti-proliferative effects in the models tested.”
What this piece can’t prove
  • Findings are from in vitro cell-line experiments; relevance to in vivo physiology or clinical outcomes is not established in this unit.

2 further details could not be confirmed from the summary.

3otherCharacterize AR binding and enhancer-like chromatin activity at a conserved intron 3 hormone response region (HRR INT3) within the ZBTB16 locus in breast cancer models and clinical specimens.Chromatin profiling at locus (AR and H3K27ac ChIP in models and clinical specimens)Expand

In plain English

AR binds a conserved intron 3 hormone response region (HRR INT3) inside the ZBTB16 locus in breast cancer models and in clinical specimens, and androgen treatment is associated with increased H3K27ac at this site, consistent with AR-responsive enhancer activity.

Key findings

  • AR occupancy was mapped to a conserved intron 3 hormone response region (HRR INT3) within the ZBTB16 locus in breast cancer models and clinical specimens.
  • Androgen exposure was associated with enrichment of H3K27ac at HRR INT3, consistent with activation of an AR-responsive enhancer.
“AR bound a conserved intron 3 hormone response region (HRR INT3 ) within the ZBTB16 locus in breast cancer models and clinical specimens, with androgen-dependent H3K27ac enrichment, consistent with an AR-responsive enhancer.”
What this piece can’t prove
  • Summary is based on abstract text only; primary paper likely contains essential experimental details (assay types, controls, sample sizes, statistical analyses) that are not available here.
  • The abstract does not report quantitative measures (e.g., fold-change, p-values) or the number/characteristics of clinical specimens assayed.
  • Unclear whether H3K27ac enrichment or AR occupancy were assessed genome-wide versus by locus-targeted assays, or how reproducible these signals were across samples.
4secondary dataAssess clinical relevance of ZBTB16 expression in human breast cancer cohorts (tumour vs normal expression; association with survival in ER+ disease).secondary data analysis (clinical cohort gene-expression and survival analysis)Expand

In plain English

Analysis of clinical cohorts found ZBTB16 mRNA expression was lower in breast tumours than in normal breast tissue, and, within ER+ breast cancer, higher ZBTB16 expression was associated with improved patient survival.

Key findings

  • ZBTB16 mRNA expression was reduced in breast tumours relative to normal breast tissue in clinical cohorts.
  • Higher ZBTB16 expression correlated with improved survival in ER+ breast cancer.
“In clinical cohorts, ZBTB16 mRNA expression was reduced in breast tumours relative to normal tissue, and higher expression correlated with improved survival in ER + disease.”
What this piece can’t prove
  • Unclear whether survival analyses adjusted for potential confounders (e.g., age, stage, treatments) or accounted for multiple testing.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

A functional role for an intronic enhancer of ZBTB16 in AR-mediated tumour suppression in ER+ breast cancer

npj Breast Cancer · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref · 40 candidate papers

Selected

A functional role for an intronic enhancer of ZBTB16 in AR-mediated tumour suppression in ER+ breast cancer

Npj Breast Cancer · 2026 · Crossref

Source (opens in a new tab)
Candidate

Obesity impairs the antitumor activity of CAR-T cells in triple-negative breast cancer

Npj Breast Cancer · 2026 · Crossref

Source (opens in a new tab)
Candidate

Next-generation PARP1-selective inhibition and combination therapy in breast cancer

Npj Breast Cancer · 2026 · Crossref

Source (opens in a new tab)

And 34 more candidates considered.